Upgrade to SI Premium - Free Trial

Marker Therapeutics (MRKR) Misses Q3 EPS by 12c

November 14, 2025 7:49 AM

Marker Therapeutics (NASDAQ: MRKR) reported Q3 EPS of ($0.12). Revenue for the quarter came in at $1.23 million.

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

Categories

Earnings